[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biotroy Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100601185","phase-1-a-clinical-study-of-bt02-in-patients-with-relapsed-or-refractory-hematologic-malignancies-100601185",false,"NCT07107204","A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies","A Multicenter, Open-label, Single-arm Phase Ib\u002FIIa Clinical Study to Evaluate the Safety and Efficacy of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n1. Voluntary participation with signed informed consent by the participant or their legal guardian and being willing and able to comply with all trial procedures.\n2. Age:≥18 and \\\u003C70 years, any gender.\n3. Diagnosis:Confirmed hematologic malignancy (leukemia, lymphoma, or multiple myeloma) .\n4. Leukemia-Specific Requirement:Bone marrow blast count ≥5% (morphological) at screening.\n5. Measurable Disease.\n6. Relapsed\u002FRefractory Status.\n7. Adequate organ and hematologic function.\n8. An ECOG activity status score of 0-1.\n9. A life expectancy of ≥ 3 months.\n10. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period.\n\nExclusion Criteria:\n\n1. Acute promyelocytic leukemia (APL).\n2. Patients with hereditary syndromes such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome.\n3. Patients with isolated extramedullary leukemia and multiple myeloma.\n4. Patients with uncontrolled active central nervous system leukemia (CNSL).\n5. Patients who have received anticancer therapy prior to administration.\n6. A history of active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years.\n7. A history of clinically significant cardiovascular disease, severe cardiac rhythm\u002Fconduction abnormalities ,severe pulmonary disease that may lead to severe episodes of dyspnea,head trauma, impaired consciousness, epilepsy, cerebral ischemia, or cerebral hemorrhagic disease.\n8. A severe acute or chronic infection when enrollment.\n9. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .\n10. Unresolved \\> grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product.\n11. Patients undergoing acute graft-versus-host disease (GVHD) or moderate-to-severe chronic GVHD or systemic GVHD therapy.\n12. A history of other type of malignancies.\n13. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product.\n14. Poor compliance.\n15. A history of alcohol\u002Fdrugs abuse.\n16. Current pregnancy or breastfeeding.\n17. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.","ALL","18 Years","70 Years",{"count":20,"type":21},116,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years .\n\nParticipants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.",[28,29,30,31],"Relapsed or Refractory Hematologic Malignancies","Leukemia","Lymphoma","Multiple Myeloma (MM)","NOT_YET_RECRUITING","2025-09-15",{"date":35,"type":36},"2025-09-17","ACTUAL",{"date":38,"type":21},"2025-10",{"date":40,"type":21},"2028-04",{"name":42,"class":43},"Biotroy Therapeutics","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100601428","phase-1-a-clinical-study-of-bt02-in-treating-patients-with-advanced-lung-cancer-100601428","NCT07110363","A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer","An Open-label Phase Ib Study on the Safety, Tolerability, and Efficacy of BT02 in Treating Patients With Advanced Lung Cancer","Inclusion Criteria:\n\n1. Patients with pathologically confirmed locally advanced\u002Funresectable or metastatic or recurrent non-small cell lung cancer (NSCLC, according to AJCC TNM staging) and advanced\u002Funresectable limited-stage or extensive-stage small cell lung cancer (SCLC, according to VALG combined with AJCC TNM staging)，who have failed in the prior systemic therapy .\n2. Adequate organ and hematologic function.\n3. At least 1 extracranial measurable lesion.\n4. An ECOG activity status score of 0-1.\n5. A life expectancy of ≥ 3 months.\n6. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period.\n7. Good compliance and willingness to follow up.\n\nExclusion Criteria:\n\n1. Patients with sensitive mutations or gene fusions related to lung cancer.\n2. Prior to the first dose , received systemic antitumor therapy, scheduled major surgical procedure within 4 weeks, received systemic immunostimulants within 5 half-lives and systemic corticosteroids or other immunosuppressive medications within 14 days.\n3. A history of active autoimmune disease within the past 2 years.\n4. A history of clinically significant cardiovascular disease, severe cardiac rhythm \u002Fconduction abnormalities or LVEF \\\u003C50% . A history of severe pulmonary disease that may lead to severe episodes of dyspnea.\n5. A severe acute or chronic infection when enrollment.\n6. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .\n7. Unresolved \\> Grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product.\n8. Clinically active CNS metastases or meningeal metastases.\n9. A history of other type of malignancies.\n10. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product.\n11. Poor compliance.\n12. A history of alcohol or drugs abuse.\n13. Current pregnancy or breastfeeding.\n14. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.","75 Years",{"count":53,"type":21},58,[24],"The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.",[57,58,59,60],"Advanced Malignant Solid Tumor","Advanced Lung Cancer","Non-Small Cell Lung Cancer","Small Cell Lung Cancer","2025-08-05",{"date":63,"type":36},"2025-08-07",{"date":65,"type":21},"2025-08",{"date":67,"type":21},"2027-05",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100601183","phase-1-a-clinical-study-of-bt02-for-the-treatment-of-patients-with-advanced-malignant-melanoma-100601183","NCT07107178","A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma","A Phase Ib Study of the Safety, Tolerability and Efficacy of BT02 for the Treatment of Patients With Advanced Malignant Melanoma","Inclusion Criteria:\n\n1. Patients with histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic malignant melanoma (except for uveal melanoma) who have failed in the prior systemic therapy .\n2. Adequate organ and hematologic function.\n3. At least 1 extracranial measurable lesion.\n4. An ECOG activity status score of 0-1.\n5. A life expectancy of ≥ 3 months.\n6. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period.\n7. Good compliance and willingness to follow up.\n\nExclusion Criteria:\n\n1. Prior to first dose, received systemic antitumor therapy , scheduled major surgical procedure within 4 weeks , received systemic immunostimulants within 5 half-lives and systemic corticosteroids or other immunosuppressive medications within 14 days.\n2. A history of active autoimmune disease within the past 2 years.\n3. A history of clinically significant cardiovascular disease, severe cardiac rhythm\u002Fconduction abnormalities or LVEF\\\u003C50%. A history of severe pulmonary disease that may lead to severe episodes of dyspnea.\n4. A severe acute or chronic infection when enrollment.\n5. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .\n6. Unresolved \\> grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product.\n7. Clinically active CNS metastases or meningeal metastases.\n8. A history of other type of malignancies.\n9. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product.\n10. Poor compliance.\n11. A history of alcohol\u002Fdrugs abuse.\n12. Current pregnancy or breastfeeding.\n13. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.",{"count":53,"type":21},[24],"The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive).\n\nParticipants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.",[80,81],"Advanced Melanoma","Advanced Solid Tumor","2025-07-30",{"date":84,"type":36},"2025-08-06",{"date":86,"type":21},"2025-08-08",{"date":88,"type":21},"2027-08",{"name":42,"class":43},""]